The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.


Robert Coleman, MD, FRCP, FRCPE
Medical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom

Wolfgang Janni, MD, PhD
University of Ulm
Ulm, Germany

Hope Rugo, MD
University of California
San Francisco, California, United States

Activity Details

Credit Type: None
Release Date: January 23, 2017
Expiration Date: January 22, 2018
Estimated Time to Complete Activity: 30 minutes
Registration Required: No
Fee for Activity: There is no fee for participating in this activity.

Activity Description

This breast cancer thought leader discussion, with associated slide deck and eNewsflash, will provide participants with valuable updates and expert perspectives on exciting new data on the treatment of advanced breast cancer released at the 2016 Annual Breast Cancer Meeting in San Antonio, Texas.


Abstract #P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2- advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial
Abstract #P4-22-05: First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial
Abstract #P4-22-03: Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies
Abstract #P4-22-06: Treatment post progression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3
Abstract #P6-11-11: Abemaciclib exposure-response relationship in patients with metastatic breast cancer in MONARCH 1
Abstract #P6-11-12: Subgroup analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2- metastatic breast cancer (MBC) following chemotherapy
Abstract #S4-07: BELLE-3: A Phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment
Abstract #S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Evaluate combinations of targeted and endocrine therapy for the first-line and second-line treatment of ER-positive, HER2-negative advanced breast cancer
  • Describe the role of cyclins and cyclin dependent kinases (CDKs) in the biology of ER-positive disease, and differentiate the range of developmental CDK4/6 inhibitors
  • Select appropriate treatment combinations for ER-positive, HER2-negative breast cancer, and identify the optimal sequence of treatment options

Target Audience

This educational activity is specifically designed for medical oncologists, translational scientists, and other healthcare professionals interested in and/or involved in the treatment of breast cancer.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.


This activity is provided by prIME Oncology.


This educational activity is supported by a grant from Novartis Oncology.

Contact Information for Questions about the Activity

Hardware / Software Requirements

Our educational activities are available on Mac, PC, and Multi-Touch devices. For the best online experience, we recommend using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox or Safari.

Depending on your browser of choice, additional software, such as Adobe Reader®, may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.